Stock BIIB34 BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 07:00:00 25/06/2024 pm IST 		5-day change 1st Jan Change
204.2 BRL +0.02% Intraday chart for Biogen Inc. +0.02% -0.47%
28/06 Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease MT
28/06 Eisai and Biogen launch Alzheimer's drug Leqembi in China RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 53,543 37,679 35,242 39,877 37,495 33,752 - -
Enterprise Value (EV) 1 51,733 41,723 37,820 40,560 43,384 36,747 34,366 30,752
P/E ratio 9.44 x 9.87 x 23.1 x 13.3 x 32.5 x 18.2 x 15.6 x 13 x
Yield - - - - - - - -
Capitalization / Revenue 3.72 x 2.8 x 3.21 x 3.92 x 3.81 x 3.55 x 3.53 x 3.41 x
EV / Revenue 3.6 x 3.1 x 3.44 x 3.99 x 4.41 x 3.86 x 3.59 x 3.11 x
EV / EBITDA 6.41 x 5.56 x 9.13 x 11.2 x 14.3 x 11 x 9.81 x 7.95 x
EV / FCF 7.88 x 11 x 11.2 x 35.5 x 34.2 x 16.2 x 12.3 x 10.6 x
FCF Yield 12.7% 9.12% 8.94% 2.82% 2.93% 6.17% 8.13% 9.45%
Price to Book 3.87 x 3.7 x 3.26 x 3.02 x 2.53 x 1.98 x 1.75 x 1.53 x
Nbr of stocks (in thousands) 1,80,442 1,53,882 1,46,893 1,44,001 1,44,898 1,45,597 - -
Reference price 2 296.7 244.9 239.9 276.9 258.8 231.8 231.8 231.8
Announcement Date 30/01/20 03/02/21 03/02/22 15/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 14,378 13,445 10,982 10,173 9,836 9,520 9,564 9,888
EBITDA 1 8,070 7,504 4,144 3,618 3,040 3,333 3,503 3,868
EBIT 1 7,390 6,837 3,656 3,099 2,545 2,881 3,090 3,352
Operating Margin 51.4% 50.85% 33.3% 30.47% 25.87% 30.27% 32.31% 33.9%
Earnings before Tax (EBT) 1 7,126 5,048 1,745 3,592 1,297 2,284 2,793 3,174
Net income 1 5,888 4,001 1,556 3,047 1,161 1,906 2,217 2,576
Net margin 40.96% 29.76% 14.17% 29.95% 11.8% 20.02% 23.18% 26.05%
EPS 2 31.42 24.80 10.40 20.87 7.970 12.74 14.82 17.85
Free Cash Flow 1 6,564 3,805 3,382 1,144 1,270 2,267 2,794 2,906
FCF margin 45.65% 28.3% 30.8% 11.25% 12.91% 23.82% 29.21% 29.38%
FCF Conversion (EBITDA) 81.34% 50.71% 81.61% 31.62% 41.79% 68.03% 79.76% 75.12%
FCF Conversion (Net income) 111.47% 95.11% 217.34% 37.55% 109.4% 118.96% 126.01% 112.78%
Dividend per Share 2 - - - - - - - -
Announcement Date 30/01/20 03/02/21 03/02/22 15/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 2,734 2,532 2,589 2,508 2,544 2,463 2,456 2,530 2,386 2,290 2,384 2,406 2,449 2,405 2,446
EBITDA 1 780.7 844.1 1,112 991 792.7 674.7 797.7 853.1 697.5 795.5 964.8 989.9 1,032 - -
EBIT 1 646 708.6 976.7 870 672.9 467.5 674.2 728.1 557.4 648 727.7 741.6 734.2 746 808
Operating Margin 23.63% 27.99% 37.72% 34.68% 26.45% 18.98% 27.45% 28.78% 23.36% 28.29% 30.52% 30.82% 29.98% 31.02% 33.03%
Earnings before Tax (EBT) 1 405 347.4 1,270 1,371 603.8 438.3 708.1 -141.2 291.6 464.8 653.1 558.2 560.3 - -
Net income 1 368.2 303.8 1,058 1,135 550.4 387.9 591.6 -68.1 249.7 393.4 535.2 482.8 485.1 457 505
Net margin 13.47% 12% 40.86% 45.23% 21.64% 15.75% 24.09% -2.69% 10.47% 17.18% 22.45% 20.06% 19.81% 19% 20.65%
EPS 2 2.500 2.060 7.240 7.840 3.790 2.670 4.070 -0.4700 1.710 2.700 3.595 3.202 3.334 3.290 3.405
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 03/02/22 03/05/22 20/07/22 25/10/22 15/02/23 25/04/23 25/07/23 08/11/23 13/02/24 24/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 4,044 2,578 683 5,888 2,995 614 -
Net Cash position 1 1,810 - - - - - - 3,000
Leverage (Debt/EBITDA) - 0.5389 x 0.6221 x 0.1888 x 1.937 x 0.8986 x 0.1752 x -
Free Cash Flow 1 6,564 3,805 3,382 1,144 1,270 2,267 2,794 2,906
ROE (net income / shareholders' equity) 47.7% 45.2% 26.6% 21.2% 15.2% 14.3% 14.6% 14.5%
ROA (Net income/ Total Assets) 24% 15.4% 11.9% 12.6% 4.52% 7.56% 7.57% 7.86%
Assets 1 24,583 25,927 13,124 24,216 25,699 25,198 29,271 32,783
Book Value Per Share 2 76.60 66.20 73.50 91.70 102.0 117.0 132.0 151.0
Cash Flow per Share 2 38.00 26.20 24.30 9.480 10.60 19.70 20.10 24.40
Capex 1 515 425 258 240 277 302 292 298
Capex / Sales 3.58% 3.16% 2.35% 2.36% 2.82% 3.17% 3.06% 3.02%
Announcement Date 30/01/20 03/02/21 03/02/22 15/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Biogen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8 USD
Average target price
283.2 USD
Spread / Average Target
+22.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+2.99% 95.18B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-4.34% 37.55B
UCB Stock UCB
+75.79% 28.2B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.61% 15.63B
INCYTE CORPORATION Stock Incyte Corporation
-3.46% 13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.31% 11.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+184.77% 10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.13% 9.23B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.22% 9.09B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. BIIB34 Stock
  5. Financials Biogen Inc.